You can buy or sell RARX and other stocks, options, ETFs, and crypto commission-free!
Ra Pharmaceuticals, Inc. Common Stock, also called Ra Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in the development of peptide-based drugs for a variety of therapeutic uses. Read More The company's product include RA101495 SC, which is an injection into the tissue under the skin, for the treatment of paroxysmal nocturnal hemoglobinuria. Ra Pharmaceuticals was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Stock Price, News, & Analysis for Ra Pharmaceuticals
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin t...
Ra Pharmaceuticals Supports 12th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today joins forces with 30 million healthcare advocates around the world for the 12th Annual Rare Disease Day®, an awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people living with rare diseases face. “ Despite important scientific advances in the treatment of rare diseases, there remains significant work to be done to help patients and families. At Ra Pharma...
-$0.52 per share
-$0.47 per share